although as many as a further 124,500 people have been incorrectly diagnosed with epilepsy in the UK. According to the NICE guidelines for epilepsy, updated in 2014, the annual estimated total cost of epilepsy in the UK is £2 billion, 3 highlighting the importance of making a correct diagnosis and initiating an appropriate treatment.
The aim of treatment is to control seizures, avoiding treatment side-effects, and maintaining or restoring quality of life. Optimal management minimises detrimental impacts on social, educational and employment activity. As with all chronic conditions, physicians should aim to empower patients with epilepsy to take an active role in their disease management, and to lead lifestyles consistent with their abilities. Drug therapy remains the mainstay mode of effective seizure control with two-thirds of people with active epilepsy achieving satisfactory control.
In this review, we cover the key issues in diagnosing epilepsy and provides a rational framework for drug prescribing in adults (aged 16 years and above). We also focus on patient groups that require special consideration, namely women of childbearing age, pregnant women and the elderly.
Diagnosis of epilepsy
A diagnosis of epilepsy should always be made by an appropriate specialist. Despite medical advances, the diagnosis of epilepsy is still fundamentally clinical and based on an accurate history from the patient, and where possible an eyewitness account of the attack(s). All patients referred for diagnosis and management should bring a witness to the first specialist consultation, or have that witness available for telephone discussion at the time of the consultation. Written accounts tend to be disappointing, emphasising the witness' opinion and This drug review looks at the key issues in diagnosing epilepsy, initiating drug therapy and empowering patients to take an active role in their disease management. It also focusses on patient groups that require special consideration such as women of childbearing age, pregnant women and the elderly.
actions, often omitting apparently minor but key points such as pallor at onset. Certain aspects of the past personal and developmental history may be relevant, such as febrile convulsions in infancy, a history of head trauma or bacterial meningitis, premature birth, and difficult or prolonged delivery at birth, all of which are associated with the development of seizures.
A detailed account of the attacks should be sought, including the presence of premonitory symptoms or signs, such as visual, auditory, olfactory or sensory auras. Sleep deprivation and alcohol may be important triggers for juvenile myoclonic epilepsy. Video recordings filmed out of hospital are increasingly accessible (eg using mobile phones) and form a useful adjunct to the clinical history, especially when seizures are infrequent, although the start of the attack is normally most important for diagnosis, whereas the video typically captures the end of the attack. Key features of an epileptic seizure include a sudden onset of collapse or loss of consciousness, shaking, jerking or repetitive movements, urinary incontinence, tongue and cheek biting, and a postictal phase characterised by confusion, irritability or drowsiness. Other seizure-related symptoms suggestive of a diagnosis of epilepsy are listed in Table 1 .
Epileptic seizures are stereotyped and occur at random, or in a pattern known in epilepsy, eg shortly after waking in juvenile myoclonic epilepsy. The main differential diagnosis of seizures assumed by non-specialists to be epilepsy, is: 1. Cardiac arrhythmia (red flags are family history of cardiac arrhythmia or an abnormal interictal ECG). This is more common than many non-specialists appear to believe. 2. Convulsive syncope (largely while standing, nausea and pallor at onset; attacks in pubs, clubs and aeroplanes; convulsion worsened by elevating the head). This is more common than epilepsy. 3. Non-epileptic (psychogenic) attacks, which tend to be dramatic and prolonged, and may be associated with history of abuse or other major psychiatric disturbance especially personality disorder.
Investigations

MRI
Patients presenting with a first seizure should undergo brain imaging. The mainstay of elective brain imaging in epilepsy is high-resolution MRI with an epilepsy protocol. MRI is especially important in the minority of individuals with refractory partial seizures who could be candidates for surgical treatment, and in those with progressive neurological or psychological deficits. The detection of subtle changes that could underlie refractory focal epilepsies, such as focal cortical dysplasia, is improving with new MRI acquisition sequences (see Figure 1) . It is noteworthy that the MRI may reveal an incidental finding in up to 25 per cent of cases, and patients should be counselled about this. Equally, a normal scan does not diminish the clinical possibility of epilepsy, nor alter the driving regulations.
EEG
An EEG can be a useful investigation for the differential diagnosis of patients with a clinical diagnosis of epilepsy, and in the management of patients with established epilepsy (see Table  2 ). The presence of a normal EEG does not rule out epilepsy, with as many as 10 per cent of patients with epilepsy never having epileptiform discharges on the EEG. 5 The sensitivity of EEG for epilepsy ranges between 25-56 per cent, with a specificity of 78-98 per cent, so an abnormal EEG does not confirm epilepsy. It is not appropriate to send an EEG with 'epilepsy?' written as a query. Abnormalities of background cerebral rhythms may indicate a localised structural pathology in the cortex, or diffuse cortical dysfunction as in symptomatic generalised epilepsies. Certain wave types, such as 3 per second spike wave discharge (see Figure 2 ) and generalised photoparoxysmal response, are strongly correlated with clinical epilepsy though do not in themselves establish a diagnosis of epilepsy.
Classification of epilepsy
The classification schemes for epilepsy are based on the widely accepted concept that seizures can be focal or generalised. A generalised seizure originates within neuronal networks in both hemispheres (although not necessarily the entire cortex). A focal seizure is thought to arise within an area confined to one hemisphere. Table 3 shows the types of epilepsy according to the latest International League Against Epilepsy (ILAE) classification. 6 Epilepsy l DRUG REVIEW n Prescriber 5 February 2015 z 13 prescriber.co.uk 
General prescribing principles
Antiepileptic drugs (AEDs) should always be introduced gradually and the dose stepped up slowly. Titration of the drug is usually symptom-led, and if seizures are still taking place, the drug should be titrated up to the maximum tolerated or maximum licensed dose. If toxic effects occur at any point, the dose should be reduced. If one first-line drug fails at the maximum tolerated dose, it should be substituted with another such drug. This needs to be done early, as withdrawal shortly before resumption of driving can be challenging. Monotherapy is always preferable because polytherapy increases the possibilities of poor compliance, drug interactions, teratogenicity and long-term toxic effects, although for about 15 per cent of individuals polytherapy cannot be avoided. There is no evidence base for choice of second AED. Patients on three or more AEDs are overmedicated, though once this is established it can be hard to reverse.
When should treatment be started in people with few or infrequent seizures?
There is no recent evidence that justifies the practice of waiting for further events rather than starting treatment immediately after a first seizure. 7 Patients perceived to be at high risk of recurrence because of a structural abnormality thought to be responsible for the seizure 8 , an abnormal EEG, a pre-existing neurological problem, or an initial high density of seizures, should still be offered AEDs at the first opportunity. The same holds true for those who, on understanding the risks of recurrence and the scope and limitations of these drugs, wish to take medication to reduce the risk of a further seizure. It is acceptable to take no AED if attacks are infrequent, particularly if they are partial seizures and the patient does not wish to drive.
Patients with generalised attacks need to know that 1 in 10,000 generalised attacks cause sudden death; it is assumed but not proven that AEDs reduce this risk.
Recent drug therapy guidelines
AEDs are the mainstay of epilepsy treatment and are effective in 60-70 per cent of individuals.
1 Treatment with AED therapy is generally recommended after a second epileptic seizure.
All treatment guidelines recommend an individualised approach to treatment according to their clinical effectiveness for the epileptic syndrome or seizure type, and for tolerability and individual patients' circumstances. Many guidelines, however, may rely too much on economic arguments and do not fully consider the side-effect profiles of lamotrigine, levetiracetam, carbamazepine and valproate. We provide a pragmatic approach to AED prescribing according to epilepsy type (see Table 4 ) that takes into account our own experience of tolerability, side-effects and adherence, as well as key recent drug trials in epilepsy.
NICE guidelines 3 suggest a range of drugs as potential firstline treatments for the different seizure types and epilepsy syndromes that are most likely to be seen in adult practice (see Table 5 ).
Focal epilepsy
First-line treatment in patients with newly diagnosed focal seizures is carbamazepine or lamotrigine. The pragmatic Standard and New Antiepileptic Drugs (SANAD) trial evaluating newer drugs in newly diagnosed epilepsy examined seizure control, tolerability, quality of life and health economic outcomes, and showed that lamotrigine was superior to carbamazepine, topiramate and gabapentin for focal epilepsy. 9 Levetiracetam, oxcarbazepine or sodium valproate can be used as alternatives if carbamazepine and lamotrigine are unsuitable or not tolerated. In accordance with NICE guidelines, clobazam, gabapentin, levetiracetam, oxcarbazepine, sodium valproate or topiramate can be used as adjunctive treatment in patients with focal seizures if first-line treatments are ineffective or not tolerated. Other AEDs
prescriber.co.uk , although it may be associated with an increased risk of non-convulsive status epilepticus in patients with partial epilepsy. 11 Levetiracetam was found to be as effective as controlledrelease carbamazepine in patients with partial seizures, with a lower (although not statistically significant) adverse rate. 12 The Keppra versus Older Monotherapy in Epilepsy Trial (KOMET) 13 also showed that levetiracetam as monotherapy was non-superior to extended-release sodium valproate or to controlled-release carbamazepine in terms of time to treatment withdrawal in patients with newly diagnosed epilepsy. There was no difference between monotherapy with levetiracetam and lamotrigine in the rate of seizure-free patients with focal seizures. 14 
Generalised epilepsy
A recent study 15 has highlighted some important general principles related to AED prescribing in patients with generalised and unclassified epilepsy. Firstly, when patients are started on AEDs there was a 44 per cent first-line treatment failure but 75 per cent subsequently achieved 12 months' remission with a second agent as monotherapy. Thus, despite initial 'drug resistance', a significant proportion of patients need to switch from their initial drug to a second drug in order to achieve seizure control. The principal causes of treatment failure were the presence and number of tonic-clonic seizures while on medication, and the presence of abnormal brain imaging (computed tomography or MRI).
As suggested from the SANAD trial, sodium valproate should be the first-line treatment in patients with newly diagnosed generalised tonic-clonic seizures. Lamotrigine, topiramate and carbamazepine are suitable alternatives if sodium valproate is poorly tolerated or contraindicated. It is noteworthy that lamotrigine and carbamazepine may exacerbate myoclonic and absence seizures. Clobazam, lamotrigine, levetiracetam, sodium valproate or topiramate may be used as adjunctive treatment if first-line treatments are ineffective or not tolerated. No difference between levetiracetam and controlled-release carbamazepine was found in a head-to-head trial evaluating six-month seizure freedom in patients with generalised seizures.
12 SANAD-II is currently under way and will compare the effectiveness and cost-effectiveness of newer AEDs including levetiracetam and zonisamide, and examine quality of life in patients with newly diagnosed epilepsy, with results expected in the near future. Early results suggest that sodium valproate may be superior to levetiracetam for generalised epilepsy. Similarly, the KOMET trial revealed that levetiracetam monotherapy was not superior to sodium valproate or to carbamazepine in newly diagnosed patients with generalised seizures. 13 No difference in the rate of seizure-free patients was found between levetiracetam and lamotrigine. 14 
Absence, myoclonic and tonic seizures
First-line treatment is sodium valproate, although for absence seizures ethosuximide is also effective. Levetiracetam or topiramate should be offered if sodium valproate is unsuitable or not tolerated. A combination of two of these three AEDs should be given as adjunctive treatment when monotherapy fails. Of note, certain AEDs such as lamotrigine, gabapentin and pregabalin may worsen juvenile myoclonic epilepsy.
Epilepsy in women
In order to enable informed decisions and choice, and to reduce misunderstandings, women with epilepsy and their partners must be given accurate information and counselling about contraception, conception, pregnancy, caring for children and breastfeeding, and menopause. In particular, women of childbearing potential should be warned about the risk of AEDs causing malformations and possible neurodevelopmental impairments in an unborn child.
To reduce such risks, all women on AEDs should be offered 5mg per day of folic acid before conception. It is recommended to refer to the BNF for individual drug advice on the interactions between AEDs and hormonal replacement and contraception.
Contraception
In women of childbearing potential, the possibility of interaction with oral contraceptives should be discussed and an assessment made as to the risks and benefits of treatment with individual drugs. The progestogen-only pill or implant are not recommended as reliable contraception in women and girls taking enzyme-inducing AEDs. Non-enzyme-inducing AEDs (sodium valproate, clonazepam, ethosuximide, zonisamide and levetiracetam) do not show any interactions with the combined oral contraceptive pill. 17 Women taking lamotrigine should be aware that the simultaneous use of any oestrogen-based contraceptive can result in a significant reduction of lamotrigine levels and affect seizure control, and that lamotrigine may in turn reduce the efficacy of the combined oral contraceptive pill. Lamotrigine levels have been shown to drop throughout pregnancy, 18 and although there are no specific guidelines, we suggest it is worthwhile measuring lamotrigine levels every four to six weeks during and immediately after pregnancy, and to titrate the dose of lamotrigine accordingly. 
Pregnancy
It is recommended that all pregnant women with epilepsy should notify their pregnancy, or allow their clinician to notify the pregnancy, to the UK Epilepsy and Pregnancy Register. In the context of pregnancy the aim is seizure freedom before conception and during pregnancy (particularly for women with generalised tonic-clonic seizures) although the risk of adverse effects of AEDs must also be considered. Women should be reassured that an increase in seizure frequency is generally unlikely in pregnancy or in the first few months after birth, and that the risk of a tonic-clonic seizure during the labour and the 24 hours after birth is low (1-4 per cent). Breastfeeding for most women taking AEDs is generally safe and should be encouraged, but one should support the mother's choice of feeding method that bests suits her and her family.
Epilepsy in the elderly
Epidemiological data suggest that epilepsy is more common in the elderly than in younger adults. In the elderly, epilepsy should be assumed to be focal, with primary generalised epilepsy being unusual. 19 As such, seizures are often not recognised in this patient group and are commonly misdiagnosed as confusion, syncope, memory impairment or vertigo. 20 AEDs that are more likely to interact with other medications should be avoided in the elderly, many of whom may be taking several drugs for other conditions. Although there have only been a few randomised controlled, double-blind studies regarding epilepsy in the elderly, the available data suggest that lamotrigine and gabapentin are superior to carbamazepine in this age group. 21, 22 The differential diagnosis of cardiac arrhythmia may need exclusion with cardiac monitoring, sometimes with an implanted loop recording device.
Main safety concerns or side-effects
All AEDs have some level of safety concern and/or side-effects and, while many of them are rare, it is important to monitor all drug use in the early stages. Adverse events as a result of taking AEDs include idiosyncratic rash, Stevens-Johnson syndrome, aplastic anaemia, hepatotoxicity, thrombocytopenia, paradoxical increase in seizures, epidermal necrolysis, multi-organ failure, hyponatraemia, toxic epidermal necrolysis and osteomalacia.
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Prescription review
In The older AEDs carbamazepine and sodium valproate account for about one quarter of prescriptions and 13 per cent of costs.
Of the top AEDs by volume, the newer agents gabapentin and lamotrigine have relatively low costs per prescription and levetiracetam and pregabalin are the most expensive. Newer but less frequently prescribed AEDs such as eslicarbazepine (Zebinix), lacosamide, perampanel (Fycompa), rufinamide (Inovelon), tiagabine and zonisamide constitute the top six by cost per prescription (excluding stiripentol, used to treat Dravet's syndrome).
However, high cost is not confined to newer agents: ethosuximide and phenytoin sodium are both within the top 50 per cent by this criterion. 
No. prescriptions (000s) NIC (£000s) Cost per prescription (£)
